CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$2.95
-0.01 (-0.34%)
Open$3.02
Previous Close$2.96
Day High$3.07
Day Low$2.89
52W High$8.21
52W Low$1.72
Volume—
Avg Volume4.67M
Market Cap642.22M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+2,036.9% upside
Current
$2.95
$2.95
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 117.86M | 104.56M | 145.29M |
| Net Income | -26,862,443 | -21,448,011 | 18.60M |
| Profit Margin | -22.8% | -21.7% | 12.8% |
| EBITDA | -32,687,262 | -27,548,703 | 25.56M |
| Free Cash Flow | — | — | 18.27M |
| Rev Growth | +12.7% | +12.7% | +5.8% |
| Debt/Equity | — | — | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |